Cytomegalovirus meningoencephalitis after rituximab treatment for primary central nervous system lymphoma.
Neurologist
; 19(2): 35-7, 2015 Jan.
Article
en En
| MEDLINE
| ID: mdl-25607329
ABSTRACT
The efficacy and safety of rituximab against B-cell lymphomas is well established. However, there has been an increased incidence of infectious complications after rituximab treatment, mostly hepatitis B reactivation and progressive multifocal leukoencephalopathy. This is the case of a 67-year-old patient with primary central nervous system lymphoma, who developed cytomegalovirus meningoencephalitis after receiving high-dose chemotherapy and rituximab. As there was no evidence of lymphoma relapse or additional immunosuppression, besides his previous treatment, an association between rituximab and cytomegalovirus meningoencephalitis cannot be ruled out.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias del Sistema Nervioso Central
/
Infecciones por Citomegalovirus
/
Anticuerpos Monoclonales de Origen Murino
/
Linfoma
/
Meningoencefalitis
/
Antineoplásicos
Límite:
Aged
/
Humans
/
Male
Idioma:
En
Revista:
Neurologist
Asunto de la revista:
NEUROLOGIA
Año:
2015
Tipo del documento:
Article
País de afiliación:
Grecia